Aurinia Pharmaceuticals Inc.

NasdaqGM AUPH

Aurinia Pharmaceuticals Inc. Capital Expenditure for the year ending December 31, 2023: USD -718.00 K

Aurinia Pharmaceuticals Inc. Capital Expenditure is USD -718.00 K for the year ending December 31, 2023, a -145.89% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Aurinia Pharmaceuticals Inc. Capital Expenditure for the year ending December 31, 2022 was USD -292.00 K, a 80.55% change year over year.
Aurinia Pharmaceuticals Inc. Capital Expenditure for the year ending December 31, 2021 was USD -1.50 M, a 79.56% change year over year.
Aurinia Pharmaceuticals Inc. Capital Expenditure for the year ending December 31, 2020 was USD -7.34 M, a -6,960.58% change year over year.
Aurinia Pharmaceuticals Inc. Capital Expenditure for the year ending December 31, 2019 was USD -104.00 K, a -38.67% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqGM: AUPH

Aurinia Pharmaceuticals Inc.

CEO	Mr. Peter S. Greenleaf M.B.A.
IPO Date	Sept. 3, 2014
Location	Canada
Headquarters	4464 Markham Street
Employees	300
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Vaccines

Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Key trends

Past 5 years